Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced a series of agreements to out-license its three clinical-stage pediatric lysosomal storage disease programs to GEMMA Biotherapeutics, Inc. (GEMMABio). The …
Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics Read More